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Hypertension in the Very Elderly - A Call to Improve
Blood Pressure Management of Our PAD PatientsBlood pressure treatment is overlooked in elderly PAD
patients, and especially in vascular surgical wards and
clinics. During the preoperative work-up of a Critial Limb
Ischemia (CLI) patient in his or her eight decade of life
pronounced ulcer pain or concomitant diseases takes pre-
cedence. Furthermore, multiple medications make us
reluctant to tamper with the drug list and adjust pre-
scriptions with the realistic view that we are indeed
surgeons and not specialists in vascular medicine. In light
of all the health problems the CLI patients suffer from,
control of hypertension is not a priority.
There are also other issues that contribute to our
unwillingness to control hypertension. Many of us remem-
ber occasional CLI patients with a quickly deteriorating foot
status and increased pain following addition of a second or
third anti-hypertensive drug. This presumed ‘‘reduction in
perfusion-pressure’’ to the foot has never been reproduced
in clinical studies and are not scientifically proven.1,2 While
it may be relevant from time to time this potential issue
with anti-hypertensive treatment is probably exaggerated
and is not a strong argument against proper blood pressure
control.
Unfortunately the scientific support for aggressive blood
pressure control in the elderly has also been weak. Few
studies are designed to evaluate anti-hypertensive treat-
ment specifically in CLI patients and most large outcome
trials enrolling general hypertensive populations have not
recruited the very elderly or only a few.3,4 There is also
relatively little data available on the effects of treating
the type of hypertension, called Isolated Systolic Hyperten-
sion that is common in older patients.
One of these concerns is no longer an issue. At the end of
March 2008 the hypertension in the very elderly trial
(HYVET) reported that it was terminated early due to
favorable results in one of its treatment arms and that it
was unethical to continue. Simultaneously the results were
published.5 HYVET enrolled 3845 patients mainly from
Europe and Asia who were 80 years of age or older and
had a sustained systolic blood pressure of 160 mm Hg or
more. The patients received either the diuretic indapamide1078-5884/$34 ª 2008 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2008.06.005or matching placebo. An angiotensin-convertingeenzyme
inhibitor was added in the active arm if necessary to
achieve the target blood pressure of 150/80 mm Hg and
the study continued for five years.
The results emphasized the value of aggressive antihy-
pertensive treatment also in the very elderly. It dismissed
the suspicion that stroke prevention has an associated cost
of increased mortality, as the incidence of fatal and non-
fatal stroke was reduced by 30% in the active treatment
arm and all cause mortality by 21%. A large reduction in
congestive heart failure was also noted (hazard ratio 0.36
95% CI 0.22e0.58). The benefit was apparent already during
the first year of treatment and despite the fact that the
population was healthier than the PAD group we usually
meet in our clinics, we should consider these results
carefully.
Despite the high age and the limited life of span of our
PAD patients there are now evidence that all should
receive antihypertensive treatment if their systolic blood
pressure is over 160 mm Hg, and the tolerability of this
treatment is probably good. Less heart failure opposes
the ‘‘poor perfusion to the foot ‘‘concept. Those of you
who already manage your patients this way should be com-
mended, while the rest of us should be able to improve
and split our attention between the vascular surgical
view and a more medicine oriented approach in favour
of our patients. Active therapy can even enhance blood
flow by improving heart failure and thus be beneficial for
the patency of the grafts we implant.6References
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